A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.
Seagen Inc.
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Aileron Therapeutics, Inc.
Daiichi Sankyo
Affimed GmbH
Dizal Pharmaceuticals
SecuraBio
Ohio State University Comprehensive Cancer Center
Affimed GmbH
University of Colorado, Denver
BeiGene
Takeda
HUYABIO International, LLC.
AstraZeneca
Columbia University
Kura Oncology, Inc.
Seagen Inc.
Pfizer
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd.
Northwestern University
University of Michigan Rogel Cancer Center
Solasia Pharma K.K.
Stanford University
University of Nebraska
Seagen Inc.
University of Nebraska
Weill Medical College of Cornell University
Therapeutic Advances in Childhood Leukemia Consortium
Eastern Cooperative Oncology Group
Asana BioSciences
Massachusetts General Hospital
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
National Institutes of Health Clinical Center (CC)
Fox Chase Cancer Center
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Spectrum Pharmaceuticals, Inc
National Institutes of Health Clinical Center (CC)
Spectrum Pharmaceuticals, Inc
Northwestern University
Eisai Inc.
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
Mayo Clinic
University of California, San Francisco
Eisai Inc.